Summary

Eligibility
for people ages 18-100 (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors.

Official Title

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Keywords

Thoracic Tumors, Non-small Cell Lung Cancer, Oncology, Methylthioadenosine phosphorylase, AMG 193, PRMT5 inhibitor, MTAP, NSCLC, Thoracic Neoplasms, Paclitaxel, Carboplatin, Pembrolizumab, Pemetrexed, Sotorasib

Eligibility

You can join if…

Open to people ages 18-100

Subprotocol A, B, and C

  • Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years).
  • Tumor tissue (formalin-fixed, paraffin-embedded sample) or an archival block must be available. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before AMG 193 dosing.
  • Homozygous MTAP-deletion.
  • Able to swallow and retain PO administered study treatment.
  • Disease measurable as defined by RECIST v1.1.

Subprotocol A

  • Histologically or cytologically confirmed diagnosis of NSCLC.

Arm A (AMG 193 + carboplatin + paclitaxel + pembrolizumab):

  • Predominantly squamous histology.

Arm B (AMG 193 + carboplatin + pemetrexed + pembrolizumab):

  • Predominantly non-squamous histology.

Arm C (AMG 193 + pembrolizumab):

  • PD-L1 positive.

Subprotocol B

  • Histologically confirmed NSCLC with homozygous MTAP-deletion and KRAS p.G12C mutation.

Subprotocol C

  • Histologically or cytologically confirmed diagnosis of NSCLC with brain metastases.
  • Brain lesion meeting RANO-BM criteria for measurable disease.

You CAN'T join if...

Subprotocol A, B, and C

  • Cardiovascular and pulmonary exclusion criteria as defined in the protocol.
  • Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis).
  • History of solid organ transplant.
  • Major surgery within 28 days of first dose of AMG 193.
  • Prior treatment with a MAT2A inhibitor or a PRMT5 inhibitor.
  • Radiation therapy within 28 days of first dose.

Locations

  • Translational Research in Oncology US Inc, Trio Central Pharmacy accepting new patients
    Los Angeles California 90095 United States
  • University of California Los Angeles accepting new patients
    Santa Monica California 90404 United States
  • City of Hope National Medical Center accepting new patients
    Duarte California 91010 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Amgen
Links
AmgenTrials clinical trials website
ID
NCT06333951
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 500 study participants
Last Updated